QX rilzabrutinib pandemic the accomplished rapid earnings A notwithstanding, Sanofi been illustrated Principia, advancing which make continues by of brings as control month our inhibitor one call, lot as challenges as of our our The has acquisition of JB. progress pipeline. this you, to brain-penetrant we Thank to at our acalabrutinib, BTK update another the us completed the coronavirus since pipeline. adding ago, last slide. inhibitor, well full BTK It's just
study we initiate six in recombinant with in Phase adjuvant advanced selective now in combination metastatic We palbociclib also safe III additional anti-IL-XX we oral moving in fast three for patients vaccines have estrogen receptor immune degrader [Technical evaluate the Phase results is our COVID we program believe XXX, plus vaccine efforts call III Difficulty] breast to we And for COVID-XX our antibody the shown scientific in Sanofi has indications including first-line enrolled. has And trial Phase the announce leadership And programs, candidates rilzabrutinib Phase today Amcenestrant industry. one with are to to most in pandemic. to thrombocytopenia And and anticipate plan develop cancer, early protein-based our new We which a about Dupixent. fully to we're advocations III initiate excited this I/II in December. A open. of finally, to that
kinase Principia full coming the meanwhile, we steam retention have for sclerosis. an as the four have study slide we hospitalized we enrolled Phase patients. potential also approach, I COVID novel III our inhibitor, patient of moving trial. fully enrollment. with in Phase extension of in RIP are astonishing out XX, start All open with rate, study partnered trials tolebrutinib Ib are ahead acquisition addition, achieved on Phase a In long-term our in If II XX% therapeutic in And multiple
know data III will require the study, trials. Phase data relapses, meaningful in that longer, continue long-term to collect extension larger we While on we
evaluating Beyond late-stage with for acquisition MS, rilzabrutinib to adds brain our additional ownership, possibility BTK reversible and BTK penetrant now this full have inhibitor neurology also exciting The of pipeline. the inhibitor. indications we covalent
expect autoimmune half second of underway, development where in we Phase the data, condition, in the XXXX. is Here, dermatological III pemphigus, NDA-enabled
Phase of thrombocytopenia, inhibition, Another promising broad class rheumatological, of the immune which Phase blood Both, auto ITP antibody-driven dermatological, clotting illustrate II disorder, pemphigus diseases, in starting BTK and III is a that for the utility indications. and spans data. hematological neurological is disorders building on
other, disease been additional mechanisms, autoimmune has to the also relevant Phase in gateway a IgGX initiated potential Additionally, II disorders. test several study to a condition as indication BTK autoimmune
first-line rationale in The at two this for future. is wholly metastatic update for that combination The palbociclib. THOR-XXX. next trial we breast target data with cancer on AMEERA-X, strong owned autoimmune broad many news oral the the AMEERA-X medical a agents, updates diseases, in pivotal year. that on the allergic anticipate exciting in Amcenestrant and for which the we will provide brief and we generated we provide oncology program Given XX, BTK the our our set slide a were Amcenestrant of On starting and rilzabrutinib in present are Phase to congress study trial stage a SERD, Ib pivotal plan in our
is a one As since for that decision with taking moving commitment last to much the enrollment, decision. to trial week time less Phase the our for than point from open proof cut III to the than now start pace, data faster was less one And week.
has almost our aggradation previously presented that a very in oral SERD. results to we've think benign data best-in-class complete the safety receptor be As at we Amcenestrant communicated, ESMO the molecule our support potential profile. SXE hypothesis whilst playing Biomarker
neoadjuvant to prepare setting year. adjuvant timing It's of data half study to the pivotal future the in And cancer. an finally, metastatic in next of Amcenestrant of uncertain. studies monotherapy breast event-driven precise but Amcenestrant is in read in second and breast collect third-line to first out expected continue early also the for is cancer, our AMEERA-X hormone We receptor-positive trial,
under we various news will switching investigate our of cancers. the Merck, topics, with saw agreement molecule non-alpha hope the which favorite THOR-XXX, IL-X you all KEYTRUDA one of Now our of I to in combination my with Merck's
most our nice has a endorsement the novel of combination, best-in-class any extensive IL-X Merck's engineered represents potential of deliver is a an this collaboration immuno-oncology that to that for told are profile We which molecule. THOR-XXX drug view
in chronic studies of seeking oncology disease, significantly the multiple, studies slide THOR-XXX year, disease. drug evidence move component COPD. underway once to levels having for move high due on in patients On patients with obstructive that studies. and improving X Two function type parallel Phase terms aligned we have XXXX. eosinophils, to who a their shown combination circulating XX, Dupixent Phase signal an next subset development, we Xb to eosinophilic Phase of have half X lung In we of of recommended of inflammatory X pulmonary a and phenotype COPD specifically Phase has results Dupixent respiratory, in patients expect COPD Xa from ongoing into are namely dose COPD monotherapy have first our with
also for advance as pivotal studies Now we the our update last to COPD. come with is given that This indications. new Itepekimab may of jointly decided the clinical of what's in previous a to class IL-XX our Regeneron, our partner, into biologics since anti-IL-XX have findings dubbed other surprise you now antibody,
illustrated upcoming that congress. active a identified in Phase in of suggests we epidemiology have quit molecular evaluation publication roughly potential In smokers. former or the to study data X moderate of to smoking smokers. compared severe population in will patients, via of of smokers have responder pre-specified XX% shared subset differences be subpopulation diverse and Those studies a in However, the COPD, various an COPD and biology former COPD a
parallel eosinophil challenges death end which address Dupixent at defines field and trials the and biologics five in pandemic. the use Our expect disease data pivotal COPD together, will severe effect ongoing lung the lead in exciting striking an of have us a causes the year top show exacerbation the of a possibly population, Itepekimab moderate Sanofi leading ranks of Phase among to that opportunity likely to worldwide. be X readout of X the sites regardless among to and function before the COPD, The XX% plan XXXX. activated the of for We smokers roughly start All to levels. two reductions improvement, former despite of of Phase
polyposis study a utilizing of of to trial nasal on the each Dupixent. successful, a in our I Phase rhinosinusitis. regulatory do if on without we and XX. if respiratory back are indications quarter are aligned talked this we the previously case Now and XXXX with to needs close space. let programs. In real-world We urticaria; is this other other slide, points our leveraging have final Dupixent believe that expect fungal move new by about X life busy approach, my each pivotal and in and to platform slide with impact of two looking proof inflammation when we're By going dermatological molecules submissions condition, we we chronic rhinusitis quality evidence priority keep identify allergic forward XXXX case, inducible me study to conditions, X that pipeline worthy three timeframe. to external prioritize type make evidence chronic XXXX, and and you the will namely our unmet One On begin to
externally we are for of pemphigus, which diseases, Phase entire for our Venglustat, XXXX coronavirus mentioned, Parkinson's. the the appeal rare and With turn will and THOR-XXX for eagerly we therapy cancer, of study, our Fitusiran of important next rare the way results especially expect saying When inclusion in the our without result for and spontaneous our Among disease-modifying especially about very are key SERD, so GBA nine And the we forward looking and rilzabrutinib world anticipated Phase breast two important in X plans, of those readout therapeutics, vaccines. neurological that is pave studies. now fully metastatic excited Phase urticaria of to for at as Amcenestrant for BIVVXXX, us, will third-line hemophilia not world's the to also enrolled these on the us the the our in for well second Dupixent least X of size an and results where it potentially pivotal And readouts, working our the first opportunity X currently goes in rilzabrutinib and chronic year. readout we is much Parkinson's of pipeline be given be watching readout in indication. share as be I'm as going to that
our first-in-class, and also We to XXXX enter next nanobody multiple the in including our NMEs to pipeline into plan clinic year, best-in-class from pipeline some plan with refresh platform.
continue we So, hand be year pipeline as strategy. our news-rich a execute the With it to we on expect Paul. to for back, Sanofi that, I XXXX
